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Background: Cardiac conduction disturbances, including new-onset left bundle branch block (LBBB), occur frequently following transcatheter 
aortic valve replacement (TAVR). Recent studies have demonstrated a possible association between new LBBB and adverse clinical events, including 
death and permanent pacemaker implantation (PPM).
methods: Patients from the PARTNER trial (randomized and continued access cohorts) treated with TAVR who had baseline and discharge/7-day 
ECGs analyzed in the ECG core lab comprised the study population. Patients with pre-existing LBBB or previous PPM were excluded. Univariate 
predictors of new-onset LBBB were identified. Clinical and echocardiographic outcomes were compared between patients with and without new 
LBBB.
results: New-onset LBBB occurred in 137 of 1299 (10.5%) patients and persisted in 6.4% at 30 days and 6.3% at 1 year. Baseline characteristics 
were similar in patients with and without new LBBB except for increased CAD (84.7% vs. 78.0%, p = 0.07), prior CABG (57.7% vs. 42.5%, p = 
0.0008), and PAD (51.5% vs. 43.4%, p = 0.07) in LBBB patients. Procedural characteristics were also similar, but new LBBB was associated with 
longer post-procedure hospital stay (6.7 vs. 6.3 days, p = 0.04). New LBBB was not associated with differences in 1-year all-cause mortality (17.0% 
vs. 18.7%, p = 0.80), stroke (6.4% vs. 5.6%, p = 0.74), or repeat hospitalization (16.6% vs. 17.7%, p =0.80). There was a trend toward more PPM 
(7.3% vs. 4.6%, p = 0.17) in patients with new LBBB. Although left ventricular ejection fraction (EF) was similar at baseline, the EF failed to improve 
in the group with new LBBB and was lower at discharge (52.2% vs. 55.8%, p = 0.0004), 30-days (53.0% vs. 56.0%, p = 0.003), and 1-year (53.4% 
vs. 57.4%, p = 0.02). The differences in EF did not correlate with significant differences in heart failure symptoms.
conclusion: New-onset LBBB occurred in 10.5% of patients who underwent TAVR with a balloon-expandable valve in the PARTNER trial. New LBBB 
was not associated with adverse clinical events including death, stroke, repeat hospitalization, or PPM implantation. There was, however, an early 
and sustained difference in EF between patients with and without new LBBB.
